ACADIA PHARMACEUTICALS INC
About ACADIA PHARMACEUTICALS INC
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.1B
- Net income
- $391.0M
- Total assets
- $1.6B
- Market cap
- $3.7B
- Gross margin
- 91.7%
- Operating margin
- 9.8%
- Net margin
- 36.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.1B
- Cost of revenue
- $89.0M
- Gross profit
- $982.5M
- Operating expenses
- $877.7M
- Operating income
- $104.8M
- Income tax
- -$252.1M
- Net income
- $391.0M
- EPS (basic)
- $2.32
- EPS (diluted)
- $2.30
Balance sheet
- Total assets
- $1.6B
- Current assets
- $1.1B
- Total liabilities
- $336.8M
- Current liabilities
- $277.1M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- $109.8M
- Investing cash flow
- -$302.6M
- Financing cash flow
- $49.9M
- Net cash flow
- -$142.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.7B
- P/E ratio
- 9.4
- EPS (diluted)
- $2.3
- Shares outstanding
- 170.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 27, 2004
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $391.0M in FY2025.
- Revenue grew 143% from FY2020 to FY2025.
- Gross margin of 91.7%, net margin 36.5%.
- Trading 23% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 9.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ACADIA PHARMACEUTICALS INC.
Write a review
News about ACADIA PHARMACEUTICALS INC
News & sentiment via Polygon.io
